Lechin F, van der Dijs B, Lechin M E, Amat J, Lechin A E, Cabrera A, Gómez F, Acosta E, Arocha L, Villa S
Section of Psychopharmacology, Central University of Venezuela School of Medicine, Caracas.
Arch Neurol. 1989 Sep;46(9):960-3. doi: 10.1001/archneur.1989.00520450030015.
Pimozide was compared with carbamazepine in a double-blind crossover trial in 48 patients with trigeminal neuralgia who were refractory to medical therapy. Pimozide treatment produced greater reduction in trigeminal neuralgia symptoms than carbamazepine treatment. All of the pimozide-treated patients improved, while only 56% of carbamazepine-treated patients were relieved of their pain. Although both drugs provoked some adverse effects, it was not necessary to interrupt the trial in any case. After this 24-week trial, all patients began receiving pimozide and were followed up according to an open-label study design. In all cases, the pimozide dosage was progressively reduced until the minimal effective dose was reached. Central and peripheral mechanisms that may underlie pimozide-induced improvement are discussed.
在一项双盲交叉试验中，对48例药物治疗无效的三叉神经痛患者比较了匹莫齐特与卡马西平的疗效。匹莫齐特治疗比卡马西平治疗能更有效地减轻三叉神经痛症状。所有接受匹莫齐特治疗的患者病情均有改善，而接受卡马西平治疗的患者中只有56%的疼痛得到缓解。尽管两种药物都引发了一些不良反应，但在任何情况下都无需中断试验。在这项为期24周的试验结束后，所有患者开始接受匹莫齐特治疗，并根据开放标签研究设计进行随访。在所有病例中，匹莫齐特剂量逐渐减少，直至达到最小有效剂量。文中讨论了匹莫齐特诱导病情改善可能的中枢和外周机制。
